查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402917

疫苗市场（疫苗：灭活疫苗、减毒活疫苗、类毒素、结合疫苗等；以及价：单价和多价疫苗）－2023-2031 年全球产业分析、规模、份额、成长、趋势和预测

Vaccines Market (Vaccine: Inactivated, Live Attenuated, Toxoid, Conjugate, and Others; and Valance: Monovalent and Multivalent) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 289 Pages | 商品交期: 2-10个工作天内

价格

疫苗市场 - 报告范围

TMR 关于全球疫苗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了该期间全球疫苗市场的收入2017-2031年，以2023年为基准年，2031年为预测年。报告中也提供了2023年至2031年全球疫苗市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解疫苗市场。

市场概况
2023年市场价值 1191 亿美元
2031 年市场价值 993 亿美元
CAGR 4.2%

该报告深入探讨了全球疫苗市场的竞争格局。全球疫苗市场的主要参与者已被确定，并且每个参与者的各种属性都已被描述。公司概况、财务状况、近期发展和 SWOT 是本报告中介绍的全球疫苗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概述

  • 介绍
  • 定义
  • 产业演变/发展
  • 概述
  • 市场动态
  • 2017-2031年全球市场分析与预测

第 5 章：关键见解

  • 监管场景
  • 主要分销策略
  • 定价分析
  • 专利
  • 技术进步
  • 疫苗类型 - 概述
  • COVID-19 大流行对该行业的影响

第 6 章：全球疫苗市场分析与预测

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依疫苗分类，2017-2031
    • 灭活
    • 活衰减
    • 类毒素
    • 共轭
    • 其他的
  • 市场吸引力分析：按疫苗

第 7 章：全球市场分析与预测：by Valance

  • 简介与定义
  • 动态
  • 市场价值预测：按Valance，2017-2031
    • 单价
    • 多价
  • 市场吸引力分析：按Valance

第 8 章：全球市场分析与预测：按管理途径

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依给药途径，2017-2031
    • 口服
    • 可注射
    • 其他的
  • 市场吸引力分析：按给药途径

第 9 章：全球市场分析与预测：依指标分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依指标划分，2017-2031
    • 流感
    • 肝炎
    • 小儿麻痹
    • 脑膜炎球菌疾病
    • 肺炎球菌疾病
    • 桌面排版
    • 轮状病毒
    • MMR
    • 人类乳突病毒
    • 其他的
  • 市场吸引力分析：依指标分类

第 10 章：全球市场分析与预测：按配销通路

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2017-2031
    • 机构销售
    • 医院药房
    • 零售药局
  • 市场吸引力分析：按配销通路

第 11 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 12 章：北美市场分析与预测

第 13 章：欧洲市场分析与预测

第 14 章：亚太市场分析与预测

第 15 章：拉丁美洲市场分析与预测

第 16 章：中东和非洲市场分析与预测

第17章：竞争格局

  • 市场参与者竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • AstraZeneca
    • GlaxoSmithKline PLC
    • Sanofi Pasteur SA
    • Pfizer Inc.
    • Panacea Biotec
    • Merck & Co., Inc.
    • Janssen Pharmaceutical Company
    • Serus Institute of India Ltd
    • Emergent BioSolutions Inc.
    • CSL
    • Bavarian Nordic
    • IBSS BIOMED SA
    • Novavax AB
    • Mitsubishi Tanabe Pharma Corporation
Product Code: TMRGL21

Vaccines Market - Scope of Report

TMR's report on the global vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global vaccines market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global vaccines market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the vaccines market.

Market Snapshot
Market Value in 2023US$ 119.1 Bn
Market Value in 2031US$ 99.3 Bn
CAGR4.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global vaccines market.

The report delves into the competitive landscape of the global vaccines market. Key players operating in the global vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global vaccines market profiled in this report.

Key Questions Answered in Global vaccines Market Report:

  • What is the sales/revenue generated by vaccines across all regions during the forecast period?
  • What are the opportunities in the global vaccines market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Vaccines Market - Research Objectives and Research Approach

The comprehensive report on the global vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global vaccines market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Vaccines Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Definition
  • 4.3. Industry Evolution / Developments
  • 4.4. Overview
  • 4.5. Market Dynamics
    • 4.5.1. Drivers
    • 4.5.2. Restraints
    • 4.5.3. Opportunities
  • 4.6. Global Vaccines Market Analysis and Forecast, 2017-2031
    • 4.6.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario
  • 5.2. Key Distribution Strategies
  • 5.3. Pricing Analysis
  • 5.4. Patents on Vaccines
  • 5.5. Technological Advancements in Vaccines
  • 5.6. Vaccine Type - Overview
  • 5.7. COVID-19 Pandemic Impact on Industry

6. Global Vaccines Market Analysis and Forecast, by Vaccine

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Vaccine, 2017-2031
    • 6.3.1. Inactivated
    • 6.3.2. Live Attenuated
    • 6.3.3. Toxoid
    • 6.3.4. Conjugate
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Vaccine

7. Global Vaccines Market Analysis and Forecast, by Valance

  • 7.1. Introduction & Definition
  • 7.2. Developments
  • 7.3. Market Value Forecast, by Valance, 2017-2031
    • 7.3.1. Monovalent
    • 7.3.2. Multivalent
  • 7.4. Market Attractiveness Analysis, by Valance

8. Global Vaccines Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Oral
    • 8.3.2. Injectable
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Vaccines Market Analysis and Forecast, by Indication

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Indication, 2017-2031
    • 9.3.1. Influenza
    • 9.3.2. Hepatitis
    • 9.3.3. Polio
    • 9.3.4. Meningococcal Disease
    • 9.3.5. Pneumococcal Disease
    • 9.3.6. DTP
    • 9.3.7. Rotavirus
    • 9.3.8. MMR
    • 9.3.9. Human Papilloma Virus
    • 9.3.10. Others
  • 9.4. Market Attractiveness Analysis, by Indication

10. Global Vaccines Market Analysis and Forecast, by Distribution Channel

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Institutional Sales
    • 10.3.2. Hospital Pharmacies
    • 10.3.3. Retail Pharmacies
  • 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Vaccines Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2017-2031
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness Analysis, by Region

12. North America Vaccines Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Vaccine, 2017-2031
    • 12.3.1. Inactivated
    • 12.3.2. Live Attenuated
    • 12.3.3. Toxoid
    • 12.3.4. Conjugate
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Valance, 2017-2031
    • 12.4.1. Monovalent
    • 12.4.2. Multivalent
  • 12.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.5.1. Oral
    • 12.5.2. Injectable
    • 12.5.3. Others
  • 12.6. Market Value Forecast, by Indication, 2017-2031
    • 12.6.1. Influenza
    • 12.6.2. Hepatitis
    • 12.6.3. Polio
    • 12.6.4. Meningococcal Disease
    • 12.6.5. Pneumococcal Disease
    • 12.6.6. DTP
    • 12.6.7. Rotavirus
    • 12.6.8. MMR
    • 12.6.9. Human Papilloma Virus
    • 12.6.10. Others
  • 12.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.7.1. Institutional Sales
    • 12.7.2. Hospital Pharmacies
    • 12.7.3. Retail Pharmacies
  • 12.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 12.8.1. U.S.
    • 12.8.2. Canada
  • 12.9. Market Attractiveness Analysis
    • 12.9.1. By Vaccine
    • 12.9.2. By Valance
    • 12.9.3. By Route of Administration
    • 12.9.4. By Indication
    • 12.9.5. By Distribution Channel
    • 12.9.6. By Country

13. Europe Vaccines Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Vaccine, 2017-2031
    • 13.3.1. Inactivated
    • 13.3.2. Live Attenuated
    • 13.3.3. Toxoid
    • 13.3.4. Conjugate
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Valance, 2017-2031
    • 13.4.1. Monovalent
    • 13.4.2. Multivalent
  • 13.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.5.1. Oral
    • 13.5.2. Injectable
    • 13.5.3. Others
  • 13.6. Market Value Forecast, by Indication, 2017-2031
    • 13.6.1. Influenza
    • 13.6.2. Hepatitis
    • 13.6.3. Polio
    • 13.6.4. Meningococcal Disease
    • 13.6.5. Pneumococcal Disease
    • 13.6.6. DTP
    • 13.6.7. Rotavirus
    • 13.6.8. MMR
    • 13.6.9. Human Papilloma Virus
    • 13.6.10. Others
  • 13.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.7.1. Institutional Sales
    • 13.7.2. Hospital Pharmacies
    • 13.7.3. Retail Pharmacies
  • 13.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 13.8.1. Germany
    • 13.8.2. U.K.
    • 13.8.3. France
    • 13.8.4. Italy
    • 13.8.5. Spain
    • 13.8.6. Rest of Europe
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Vaccine
    • 13.9.2. By Valance
    • 13.9.3. By Route of Administration
    • 13.9.4. By Indication
    • 13.9.5. By Distribution Channel
    • 13.9.6. By Country/Sub-region

14. Asia Pacific Vaccines Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Vaccine, 2017-2031
    • 14.3.1. Inactivated
    • 14.3.2. Live Attenuated
    • 14.3.3. Toxoid
    • 14.3.4. Conjugate
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Valance, 2017-2031
    • 14.4.1. Monovalent
    • 14.4.2. Multivalent
  • 14.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.5.1. Oral
    • 14.5.2. Injectable
    • 14.5.3. Others
  • 14.6. Market Value Forecast, by Indication, 2017-2031
    • 14.6.1. Influenza
    • 14.6.2. Hepatitis
    • 14.6.3. Polio
    • 14.6.4. Meningococcal Disease
    • 14.6.5. Pneumococcal Disease
    • 14.6.6. DTP
    • 14.6.7. Rotavirus
    • 14.6.8. MMR
    • 14.6.9. Human Papilloma Virus
    • 14.6.10. Others
  • 14.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.7.1. Institutional Sales
    • 14.7.2. Hospital Pharmacies
    • 14.7.3. Retail Pharmacies
  • 14.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 14.8.1. China
    • 14.8.2. India
    • 14.8.3. Japan
    • 14.8.4. Australia & New Zealand
    • 14.8.5. Rest of Asia Pacific
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Vaccine
    • 14.9.2. By Valance
    • 14.9.3. By Route of Administration
    • 14.9.4. By Indication
    • 14.9.5. By Distribution Channel
    • 14.9.6. By Country/Sub-region

15. Latin America Vaccines Market Analysis and Forecast

  • 15.1. Introduction
  • 15.2. Key Findings
  • 15.3. Market Value Forecast, by Vaccine, 2017-2031
    • 15.3.1. Inactivated
    • 15.3.2. Live Attenuated
    • 15.3.3. Toxoid
    • 15.3.4. Conjugate
    • 15.3.5. Others
    • 15.3.6. Others
  • 15.4. Market Value Forecast, by Valance, 2017-2031
    • 15.4.1. Monovalent
    • 15.4.2. Multivalent
  • 15.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.5.1. Oral
    • 15.5.2. Injectable
    • 15.5.3. Others
  • 15.6. Market Value Forecast, by Indication, 2017-2031
    • 15.6.1. Influenza
    • 15.6.2. Hepatitis
    • 15.6.3. Polio
    • 15.6.4. Meningococcal Disease
    • 15.6.5. Pneumococcal Disease
    • 15.6.6. DTP
    • 15.6.7. Rotavirus
    • 15.6.8. MMR
    • 15.6.9. Human Papilloma Virus
    • 15.6.10. Others
  • 15.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.7.1. Institutional Sales
    • 15.7.2. Hospital Pharmacies
    • 15.7.3. Retail Pharmacies
  • 15.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 15.8.1. Brazil
    • 15.8.2. Mexico
    • 15.8.3. Rest of Latin America
  • 15.9. Market Attractiveness Analysis
    • 15.9.1. By Vaccine
    • 15.9.2. By Valance
    • 15.9.3. By Route of Administration
    • 15.9.4. By Indication
    • 15.9.5. By Distribution Channel
    • 15.9.6. By Country/Sub-region

16. Middle East & Africa Vaccines Market Analysis and Forecast

  • 16.1. Introduction
  • 16.2. Key Findings
  • 16.3. Market Value Forecast, by Vaccine, 2017-2031
    • 16.3.1. Inactivated
    • 16.3.2. Live Attenuated
    • 16.3.3. Toxoid
    • 16.3.4. Conjugate
    • 16.3.5. Others
  • 16.4. Market Value Forecast, by Valance, 2017-2031
    • 16.4.1. Monovalent
    • 16.4.2. Multivalent
  • 16.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 16.5.1. Oral
    • 16.5.2. Injectable
    • 16.5.3. Others
  • 16.6. Market Value Forecast, by Indication, 2017-2031
    • 16.6.1. Influenza
    • 16.6.2. Hepatitis
    • 16.6.3. Polio
    • 16.6.4. Meningococcal Disease
    • 16.6.5. Pneumococcal Disease
    • 16.6.6. DTP
    • 16.6.7. Rotavirus
    • 16.6.8. MMR
    • 16.6.9. Human Papilloma Virus
    • 16.6.10. Others
  • 16.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 16.7.1. Institutional Sales
    • 16.7.2. Hospital Pharmacies
    • 16.7.3. Retail Pharmacies
  • 16.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 16.8.1. GCC Countries
    • 16.8.2. South Africa
    • 16.8.3. Rest of Middle East & Africa
  • 16.9. Market Attractiveness Analysis
    • 16.9.1. By Vaccine
    • 16.9.2. By Valance
    • 16.9.3. By Route of Administration
    • 16.9.4. By Indication
    • 16.9.5. By Distribution Channel
    • 16.9.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player Competition Matrix (by tier and size of companies)
  • 17.2. Market Share Analysis, by Company (2022)
  • 17.3. Company Profiles
    • 17.3.1. AstraZeneca
      • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. Financial Overview
      • 17.3.1.4. SWOT Analysis
      • 17.3.1.5. Strategic Overview
    • 17.3.2. GlaxoSmithKline PLC
      • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. Financial Overview
      • 17.3.2.4. SWOT Analysis
      • 17.3.2.5. Strategic Overview
    • 17.3.3. Sanofi Pasteur SA
      • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. Financial Overview
      • 17.3.3.4. SWOT Analysis
      • 17.3.3.5. Strategic Overview
    • 17.3.4. Pfizer Inc.
      • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. Financial Overview
      • 17.3.4.4. SWOT Analysis
      • 17.3.4.5. Strategic Overview
    • 17.3.5. Panacea Biotec
      • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. Financial Overview
      • 17.3.5.4. SWOT Analysis
      • 17.3.5.5. Strategic Overview
    • 17.3.6. Merck & Co., Inc.
      • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. Financial Overview
      • 17.3.6.4. SWOT Analysis
      • 17.3.6.5. Strategic Overview
    • 17.3.7. Janssen Pharmaceutical Company
      • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. Financial Overview
      • 17.3.7.4. SWOT Analysis
      • 17.3.7.5. Strategic Overview
    • 17.3.8. Serus Institute of India Ltd
      • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. Financial Overview
      • 17.3.8.4. SWOT Analysis
      • 17.3.8.5. Strategic Overview
    • 17.3.9. Emergent BioSolutions Inc.
      • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. Financial Overview
      • 17.3.9.4. SWOT Analysis
      • 17.3.9.5. Strategic Overview
    • 17.3.10. CSL
      • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. Financial Overview
      • 17.3.10.4. SWOT Analysis
      • 17.3.10.5. Strategic Overview
    • 17.3.11. Bavarian Nordic
      • 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.11.2. Product Portfolio
      • 17.3.11.3. Financial Overview
      • 17.3.11.4. SWOT Analysis
      • 17.3.11.5. Strategic Overview
    • 17.3.12. IBSS BIOMED S.A.
      • 17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.12.2. Product Portfolio
      • 17.3.12.3. Financial Overview
      • 17.3.12.4. SWOT Analysis
      • 17.3.12.5. Strategic Overview
    • 17.3.13. Novavax AB
      • 17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.13.2. Product Portfolio
      • 17.3.13.3. Financial Overview
      • 17.3.13.4. SWOT Analysis
      • 17.3.13.5. Strategic Overview
    • 17.3.14. Mitsubishi Tanabe Pharma Corporation
      • 17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.14.2. Product Portfolio
      • 17.3.14.3. Financial Overview
      • 17.3.14.4. SWOT Analysis
      • 17.3.14.5. Strategic Overview

List of Tables

  • Table 01. Global Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 02. Global Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 03. Global Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04. Global Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 05. Global Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06. Global Vaccines Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 07. North America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 08. North America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 09. North America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 10. North America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 11. North America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12. Europe Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13. Europe Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 14. Europe Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 15. Europe Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16. Europe Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 17. Europe Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 19. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 20. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 21. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 22. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 23. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24. Latin America Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 25. Latin America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 26. Latin America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 27. Latin America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 28. Latin America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 29. Latin America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 30. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 31. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 32. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 33. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 34. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 35. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01. Global Vaccines Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02. Vaccines Market Value Share, by Vaccine, 2022
  • Figure 03. Vaccines Market Value Share, by Valance, 2022
  • Figure 04. Vaccines Market Value Share, by Route of Administration, 2022
  • Figure 05. Vaccines Market Value Share, by Indication, 2022
  • Figure 06. Vaccines Market Value Share, by Distribution Channel, 2022
  • Figure 07. Global Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 08. Global Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 09. Global Vaccines Market Value Share Analysis, by Valance 2022 and 2031
  • Figure 10. Global Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 11. Global Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 12. Global Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 13. Global Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 14. Global Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 15. Global Vaccines Market Value Share Analysis, by Distribution Channel 2022 and 2031
  • Figure 16. Global Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 17. Global Vaccines Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 18. Global Vaccines Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 19. North America Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 20. North America Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 21. North America Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 22. North America Vaccines Market Value Share Analysis, by Valance 2022 and 2031
  • Figure 23. North America Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 24. North America Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 25. North America Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 26. North America Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 27. North America Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 28. North America Vaccines Market Value Share Analysis, by Distribution Channel 2022 and 2031
  • Figure 29. North America Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 30. Europe Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 31. Europe Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 32. Europe Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 33. Europe Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 34. Europe Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 35. Europe Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
  • Figure 36. Europe Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 37. Europe Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 38. Europe Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 39. Europe Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 40. Europe Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 41. Europe Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42. Europe Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 43. Asia Pacific Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 44. Asia Pacific Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 45. Asia Pacific Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 46. Asia Pacific Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 47. Asia Pacific Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 48. Asia Pacific Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
  • Figure 49. Asia Pacific Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 50. Asia Pacific Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 51. Asia Pacific Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 52. Asia Pacific Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 53. Asia Pacific Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 54. Asia Pacific Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 55. Asia Pacific Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 56. Latin America Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 57. Latin America Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 58. Latin America Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 59. Latin America Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 60. Latin America Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 61. Latin America Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
  • Figure 62. Latin America Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 63. Latin America Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 64. Latin America Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 65. Latin America Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 66. Latin America Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 67. Latin America Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 68. Latin America Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 69. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 70. Middle East & Africa Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 71. Middle East & Africa Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 72. Middle East & Africa Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 73. Middle East & Africa Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 74. Middle East & Africa Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
  • Figure 75. Middle East & Africa Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 76. Middle East & Africa Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 77. Middle East & Africa Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 78. Middle East & Africa Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 79. Middle East & Africa Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 80. Middle East & Africa Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 81. Middle East & Africa Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031